News

The US Food and Drug Administration has approved the blood-thinning drug Effient tablets to reduce the risk of blood clots from forming in patients who undergo angioplasty, a

Eli Lilly has received the European Commission approval for the use of Alimta (pemetrexed for injection) as monotherapy. It is for maintenance treatment of patients with other than

Vertex Pharmaceuticals is expected to sell the rights to certain milestone payments tied to the future regulatory filing, approval and market launch of its hepatitis C virus (HCV)

Mentor Capital has acquired 20% stake in Quantum Immunologics, where Mentor Capital will provide equity funding to support Quantum Immunologics (QI) to complete the Phase I/II trials on

Addex, in an exclusive collaboration and license agreement with Merck & Co., has achieved the second preclinical milestone. The collaboration is focused on developing an emerging type of

Glenmark Generics is all set to launch Fosinopril Sodium and Hydrochlorothiazide tablets in the US market. Fosinopril Sodium and Hydrochlorothiazide (HCTZ) tablets are available in both 10mg/12.5mg and

Daiichi Sankyo and Eli Lilly have received approval for Effient (prasugrel) tablets from the FDA, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with

InNexus and Genhelix have signed a Letter of Intent to set the stage for a planned strategic collaboration, to focus on developing novel antibodies engineered with InNexus’ DXL

Cardinal Health board of directors has approved the spinoff of CareFusion through a pro rata distribution of at least 80% of the shares of CareFusion common stock to